Two-drug treatment for recurrent high-grade brain tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (temozolomide and dexbrompheniramine) to treat high-grade gliomas that have come back after standard treatment. The goal is to see if this combination can help control the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 19 or older, and have been diagnosed with a high-grade glioma (grade 3 or 4), including glioblastoma or gliosarcoma.
- You have received prior radiation and standard chemotherapy (temozolomide).
- If you are in the phase II part, your tumor must have grown during or shortly after the first 6 cycles of temozolomide.
- It has been at least 3 months since you finished radiation and chemotherapy, or there is clear proof the tumor has grown.
- You have recovered from side effects of earlier treatments and are otherwise healthy enough to take the study drugs.
- You have adequate blood cell counts, kidney and liver function, and a good performance status (able to care for yourself).
- You are not pregnant or breastfeeding, and if you can have children, you agree to use an effective birth control method during treatment and for a few months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests an investigational drug (PCI-24781) together with Temodar in people whose high-grade glioma (grade III/IV) has come back after prior treatment. It aims to find a safe dose and see how well the combination may work for recurrent disease.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This study tests a combination of three treatments for newly diagnosed high-grade glioma: a drug called ADI-PEG 20, chemotherapy (temozolomide), and radiation therapy. The goal is to see if this combination is safe and effective for children and young adults with this type of brain or spinal cord tumor.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.